ASND Intrinsic Valuation and Fundamental Analysis - Ascendis Pharma A/S - Alpha Spread

Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 141.1 USD 18.35%
Market Cap: 8.1B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Intrinsic Value

The intrinsic value of one ASND stock under the Base Case scenario is 158.34 USD. Compared to the current market price of 141.1 USD, Ascendis Pharma A/S is Undervalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ASND Intrinsic Value
158.34 USD
Undervaluation 11%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Ascendis Pharma A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ASND cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ASND?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Ascendis Pharma A/S

Provide an overview of the primary business activities
of Ascendis Pharma A/S.

What unique competitive advantages
does Ascendis Pharma A/S hold over its rivals?

What risks and challenges
does Ascendis Pharma A/S face in the near future?

Summarize the latest earnings call
of Ascendis Pharma A/S.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ascendis Pharma A/S.

Provide P/S
for Ascendis Pharma A/S.

Provide P/E
for Ascendis Pharma A/S.

Provide P/OCF
for Ascendis Pharma A/S.

Provide P/FCFE
for Ascendis Pharma A/S.

Provide P/B
for Ascendis Pharma A/S.

Provide EV/S
for Ascendis Pharma A/S.

Provide EV/GP
for Ascendis Pharma A/S.

Provide EV/EBITDA
for Ascendis Pharma A/S.

Provide EV/EBIT
for Ascendis Pharma A/S.

Provide EV/OCF
for Ascendis Pharma A/S.

Provide EV/FCFF
for Ascendis Pharma A/S.

Provide EV/IC
for Ascendis Pharma A/S.

Show me price targets
for Ascendis Pharma A/S made by professional analysts.

What are the Revenue projections
for Ascendis Pharma A/S?

How accurate were the past Revenue estimates
for Ascendis Pharma A/S?

What are the Net Income projections
for Ascendis Pharma A/S?

How accurate were the past Net Income estimates
for Ascendis Pharma A/S?

What are the EPS projections
for Ascendis Pharma A/S?

How accurate were the past EPS estimates
for Ascendis Pharma A/S?

What are the EBIT projections
for Ascendis Pharma A/S?

How accurate were the past EBIT estimates
for Ascendis Pharma A/S?

Compare the revenue forecasts
for Ascendis Pharma A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ascendis Pharma A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ascendis Pharma A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ascendis Pharma A/S compared to its peers.

Compare the P/E ratios
of Ascendis Pharma A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Ascendis Pharma A/S with its peers.

Analyze the financial leverage
of Ascendis Pharma A/S compared to its main competitors.

Show all profitability ratios
for Ascendis Pharma A/S.

Provide ROE
for Ascendis Pharma A/S.

Provide ROA
for Ascendis Pharma A/S.

Provide ROIC
for Ascendis Pharma A/S.

Provide ROCE
for Ascendis Pharma A/S.

Provide Gross Margin
for Ascendis Pharma A/S.

Provide Operating Margin
for Ascendis Pharma A/S.

Provide Net Margin
for Ascendis Pharma A/S.

Provide FCF Margin
for Ascendis Pharma A/S.

Show all solvency ratios
for Ascendis Pharma A/S.

Provide D/E Ratio
for Ascendis Pharma A/S.

Provide D/A Ratio
for Ascendis Pharma A/S.

Provide Interest Coverage Ratio
for Ascendis Pharma A/S.

Provide Altman Z-Score Ratio
for Ascendis Pharma A/S.

Provide Quick Ratio
for Ascendis Pharma A/S.

Provide Current Ratio
for Ascendis Pharma A/S.

Provide Cash Ratio
for Ascendis Pharma A/S.

What is the historical Revenue growth
over the last 5 years for Ascendis Pharma A/S?

What is the historical Net Income growth
over the last 5 years for Ascendis Pharma A/S?

What is the current Free Cash Flow
of Ascendis Pharma A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ascendis Pharma A/S.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ascendis Pharma A/S

Current Assets 627.3m
Cash & Short-Term Investments 258.7m
Receivables 80.7m
Other Current Assets 287.9m
Non-Current Assets 131m
Long-Term Investments 20.6m
PP&E 104m
Intangibles 4.2m
Other Non-Current Assets 2.2m
Current Liabilities 851.4m
Accounts Payable 99.5m
Short-Term Debt 432.2m
Other Current Liabilities 319.7m
Non-Current Liabilities 228m
Long-Term Debt 219.1m
Other Non-Current Liabilities 8.9m
Efficiency

Earnings Waterfall
Ascendis Pharma A/S

Revenue
317.6m EUR
Cost of Revenue
-45.9m EUR
Gross Profit
271.7m EUR
Operating Expenses
-625.2m EUR
Operating Income
-353.4m EUR
Other Expenses
-136.1m EUR
Net Income
-489.5m EUR

Free Cash Flow Analysis
Ascendis Pharma A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Ascendis Pharma saw significant market adjustments in the first half of 2024, affecting their revenue. Despite a 27% drop in Q2 2024 revenue for SKYTROFA compared to last year, volume more than doubled. Revenue was adjusted by a EUR 27.1 million true-up. YORVIPATH saw initial success in Europe, with EUR 5.2 million in Q2 revenue. Full-year 2024 SKYTROFA revenue is projected at EUR 220-240 million, and total operating expenses are expected to be around EUR 600 million. Ascendis aims to break even by 2025, driven by expanded market access and new product launches .

What is Earnings Call?
Fundamental Scores

ASND Profitability Score
Profitability Due Diligence

Ascendis Pharma A/S's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional ROE
47/100
Profitability
Score

Ascendis Pharma A/S's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

ASND Solvency Score
Solvency Due Diligence

Ascendis Pharma A/S's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
High Altman Z-Score
Positive Net Debt
Short-Term Solvency
43/100
Solvency
Score

Ascendis Pharma A/S's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 199.45 USD with a low forecast of 166.65 USD and a high forecast of 290.85 USD.

Lowest
Price Target
166.65 USD
18% Upside
Average
Price Target
199.45 USD
41% Upside
Highest
Price Target
290.85 USD
106% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ASND?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for ASND is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about ASND dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

ASND Price
Ascendis Pharma A/S

1M 1M
+2%
6M 6M
-4%
1Y 1Y
+38%
3Y 3Y
-11%
5Y 5Y
+34%
10Y 10Y
+649%
Annual Price Range
141.1
52w Low
86.1
52w High
159.4
Price Metrics
Average Annual Return 5.67%
Standard Deviation of Annual Returns 24.5%
Max Drawdown -62%
Shares Statistics
Market Capitalization 8.2B USD
Shares Outstanding 57 138 400
Percentage of Shares Shorted 8.67%

Competitive Landscape

Profile

Ascendis Pharma A/S Logo
Ascendis Pharma A/S

Country

Denmark

Industry

Biotechnology

Market Cap

8.2B USD

Dividend Yield

0%

Description

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The firm is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Contact

Hellerup
Tuborg Boulevard 12
+4570222244.0
ascendispharma.dk

IPO

2015-01-28

Employees

639

Officers

See Also

Discover More
What is the Intrinsic Value of one ASND stock?

The intrinsic value of one ASND stock under the Base Case scenario is 158.34 USD.

Is ASND stock undervalued or overvalued?

Compared to the current market price of 141.1 USD, Ascendis Pharma A/S is Undervalued by 11%.

Back to Top